Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gauging the Risks of Financing Convergence Start-Ups

This article was originally published in Start Up

Executive Summary

A handful of recent biotech-device company deals have highlighted the potential of drug-device convergence as natural extensions of the ever-popular repurposing and drug delivery models espoused by investors aiming to reduce the risks associated with drug discovery. Venture capitalists are eager to get in on the game, but drug and device hybrid business models are few and far between. True convergence start-ups remain thin on the ground, a fact VCs say reflects the additive nature of drug risk and device risk.

You may also be interested in...



Step-Ups in Convergence Plays

The rationale for drug-device convergence companies-combining the device sector's speed to market and relative lack of clinical risk with the biopharma sector's margins-may be gaining some traction as of late. Half of the eight device IPOs to close so far this year, in fact, are arguably convergence plays.

Step-Ups in Convergence Plays

The rationale for drug-device convergence companies-combining the device sector's speed to market and relative lack of clinical risk with the biopharma sector's margins-may be gaining some traction as of late. Half of the eight device IPOs to close so far this year, in fact, are arguably convergence plays.

Stem Cells: What's the Business Model?

The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091017

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel